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1. Introduction 
Traditional pathology concentrates on the morphological manifestations of disease. 
Molecular pathology, in addition, integrates tools of molecular biology to: isolate and 
identify the causative agents in infectious disease, understand the role of differential gene 
expression in disease etiology, provide more accurate means of disease diagnosis and 
provide more individualized approaches to therapy. 
Molecular pathology is a branch of the biomedical sciences which focuses on the progress, 
development, and evolution of diseases on the molecular level. It can be applied practically 
to patients in addition to being utilized in biomedical research to learn more about specific 
diseases, ranging from cancer to genetic conditions. Usually, molecular pathology is treated 
as a subset of the field of pathology, but it also involves genetics, immunology, and many 
other aspects of the medical field, and people can approach it from a number of 
perspectives. 
A molecular pathologist can conduct a variety of tests to learn about the fundamental 
components of a cell, including the array of amino acids which makes up cellular DNA. In 
addition to performing amino acid sequencing, people in this field also look at samples of 
cellular tissue, and they perform a variety of tests to learn more about the progress of 
disease in specific patients and in general. 
To understand the causes and molecular basis of the development of disease, with particular 
reference to cancer, and to apply this knowledge to improving disease prevention, detection, 
diagnosis and treatment. Improving the outlook for cancer patients can only come from an 
understanding of molecular and cell biology. There has been a dramatic increase in 
knowledge of the molecular genetics of cancers over the last few years and already we have 
reached the point where this can be translated into clinical application. 
Many diseases are caused by inherited gene mutations, for example, cystic fibrosis, 
muscular dystrophy and lysosomal storage diseases. Other gene alterations confer a greater 
susceptibility to disease – for example, cancer or heart disease. 
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One common use for a molecular pathologist is in the study of specimens taken from cancer 
patients. The pathologist can test the specimen to determine where the cancer originated, 
and to look for biomarkers which could indicate susceptibility to specific cancer treatments. 
For example, a breast cancer which is estrogen sensitive will be treated differently than a 
breast cancer which is not. Using molecular pathology, an oncologist can develop a 
treatment approach which is tailored to the patient. 
Key techniques used in molecular pathology to identify relationships between gene 
alterations and disease include cell isolation and cell culture. Immunohistochemistry is not 
considered a molecular technique but it is based on the antigen-antibody affinity, it has 
emerged as a powerful investigative tool that can provide supplemental information to the 
routine morphological assessment of tissues. The antibody is usually linked to other 
molecules to aid visualization [(fluorophore, reporter enzyme, etc), FISH (A cytogenetic 
method of detecting and localizing specific DNA sequences on chromosomes)] and 
laboratory molecular biology techniques (identification of gene mutations, expression 
profiling, protein analysis, blotting, microarrays). 
It is thought that the development of malignant disease progresses through defined stages 
such as hyperplasia, dysplasia, carcinoma in situ, primary carcinoma, invasive carcinoma 
and metastases, each of which may be linked to mutations and alterations in the expression 
of subsets of genes. Laser microdissection is useful for isolating particular cells, or 
populations of cells, from tissue (frozen sections, fixed sections and in cell culture 
monolayers) for genetic analysis allowing direct comparison of nucleic acid from cells in 
different stages of disease progression.  
 
Figure 1. Automated Cellular Imaging System (ACISR III), an example of an image acquisition and 
image analysis instrument. 
 
Figure 2.  
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The impact of gene alterations on protein function and disease can be investigated using a 
variety of imaging techniques (Figs.1 and 2). Of particular importance is the imaging of 
protein-protein interactions using time-lapse imaging, TIRF microscopy and confocal 
fluorescence microscopy techniques such as 3-D rendering, FRET/BRET. These enable 
spatial and temporal analysis of dynamic events involving, for example, receptor 
interactions and other signaling events (Fig.3). 
 
Figure 3. Nikon's powerful fully-automated confocal imaging system, capable of capturing high-quality 
confocal images of cells and molecular events. 
1.1. Immune system (tumor immunology) 
Another important role of the immune system (Fig.4) is to identify and eliminate tumors. 
The transformed cells of tumors express antigens that are not found on normal cells. To the 
immune system, these antigens appear foreign, and their presence causes immune cells to 
attack the transformed tumor cells. The antigens expressed by tumors have several sources 
[1] some are derived from oncogenic viruses like human papillomavirus, which causes 
cervical cancer,[2] while others are the organism's own proteins that occur at low levels in 
normal cells but reach high levels in tumor cells. One example is an enzyme called 
tyrosinase that, when expressed at high levels, transforms certain skin cells (e.g. 
melanocytes) into tumors called melanomas [3, 4]. A third possible source of tumor antigens 
are proteins normally important for regulating cell growth and survival, that commonly 
mutate into cancer inducing molecules called oncogenes [1,5,6]. 
The main response of the immune system to tumors is to destroy the abnormal cells using 
killer T cells, sometimes with the assistance of helper T cells [4, 7]. Tumor antigens are 
presented on MHC class I molecules in a similar way to viral antigens. This allows killer T 
cells to recognize the tumor cell as abnormal [8] NK cells also kill tumorous cells in a similar 
way, especially if the tumor cells have fewer MHC class I molecules on their surface than 
normal; this is a common phenomenon with tumors [9] .Sometimes antibodies are generated 
against tumor cells allowing for their destruction by the complement system [5]. 
Clearly, some tumors evade the immune system and go on to become cancers [10]. Tumor 
cells often have a reduced number of MHC class I molecules on their surface, thus avoiding 
detection by killer T cells [8]. Some tumor cells also release products that inhibit the immune 
response; for example by secreting the cytokine TGF-β, which suppresses the activity of 
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macrophages and lymphocytes [11]. In addition, immunological tolerance may develop 
against tumor antigens, so the immune system no longer attacks the tumor cells [10]. 
Paradoxically, macrophages can promote tumor growth [12] when tumor cells send out 
cytokines that attract macrophages, which then generate cytokines and growth factors that 
nurture tumor development. In addition, a combination of hypoxia in the tumor and a 
cytokine produced by macrophages induces tumor cells to decrease production of a protein 
that blocks metastasis and thereby assists spread of cancer cells. 
 
Figure 4. The immune system protects the body from potentially harmful substances. The 
inflammatory response (inflammation) is part of innate immunity. It occurs when tissues are injured by 
bacteria, trauma, toxins, heat or any other cause. 
1.2. Genetic diseases (genetic disorders) 
A genetic disorder is an illness caused by abnormalities in genes or chromosomes, especially 
a condition that is present from before birth. Most genetic disorders are quite rare and affect 
one person in every several thousands or millions. 
A genetic disorder may or may not be a heritable disorder. Some genetic disorders are 
passed down from the parents' genes, but others are always or almost always caused by 
new mutations or changes to the DNA. In other cases, the same disease, such as some forms 
of cancer, may be caused by an inherited genetic condition in some people, by new 
mutations in other people, and by non-genetic causes in still other people. 
2. Methods in molecular pathology 
Nucleic acid–based testing is becoming a crucial diagnostic tool not only in the setting of 
inherited genetic disease (e.g., cystic fibrosis and hemochromatosis) but also in a wide 
variety of hemato-oncologic, solid neoplastic and infectious conditions. Molecular 
diagnostics provides the necessary underpinnings for any successful application of gene 
therapy or biologic response modifiers. It offers a great tool for assessing therapy response 
and detecting minimal residual disease. Currently, it is estimated that more than 5% of all 
laboratory testing is based on DNA or RNA analysis. 
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2.1. Tissue microdissection methods 
Microdissection can be performed in a variety of ways, all of which have different 
advantages and disadvantages. These methods range from the simple and inexpensive 
manual methods to laser-capture microdissection (LCM) methods that require expensive 
and complex equipment. These methods are reviewed here, with particular emphasis on 
manual microdissection, which can be performed easily with common equipment in the 
pathology laboratory (Fig. 5). 
One of the major benefits of microdissection is the production of relatively pure samples of 
morphologically confirmed cellular populations [13]. This relative purity may be essential 
for assessing a genetic change or for quantification of genetic changes. For example, in 
assessing possible loss of heterozygosity of tumor suppressor genes, normal contaminating 
cells will artifactually equalize the allelic balance, and it may appear that the tumor cells 
contain normal DNA. In molecular identity testing for tissue floaters (tissue carryover 
artifacts), microdissection is essential for separating the fragments of the suspected floater 
from the rest of the tissue sample [14, 15] . When examining expression of some gene targets 
in tumor cells at the mRNA level, results may be confounded by the expression found in 
normal contaminating stromal and lymphoid cells. In some diseases it may be important to 
measure events in rare single neoplastic cells [16-18] . Perhaps the most notable example is 
in Hodgkin lymphoma, where molecular experiments require detailed microdissection to 
isolate the Reed-Sternberg cells from the surrounding lymphoid infiltrates. 
 
Figure 5. This method "microdissection", can be performed easily with common equipment in the 
pathology laboratory. 
2.2. Amplification methods 
The polymerase chain reaction (PCR) is a laboratory technique for "amplifying" a specific 
DNA sequence (Fig.6). PCR is extremely efficient and sensitive; it can make millions or 
billions of copies of any specific sequence of DNA, even when the sequence is in a complex 
mixture. Because of this power, researchers can use it to amplify sequences even if they only 
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have a minute amount of DNA. A single hair root, or a microscopic blood stain left at a 
crime scene, for example, contains ample DNA for PCR. 
PCR is based on the way cells replicate their DNA. During DNA replication, the two strands 
of each DNA molecule separate, and DNA polymerase, an enzyme, assembles nucleotides to 
form two new partner strands for each of the original strands. The original strands serve as 
templates for the new strands. The new strands are assembled such that each nucleotide in 
the new strand is determined by the corresponding nucleotide in the template strand. The 
nucleotides adenine (A) and thymine (T) always lie opposite each other, as do cytosine (C) 
and guanine (G). Because of this base-pairing specificity, each newly synthesized partner 
strand has the same sequence as the original partner strand, and replication produces two 
identical copies of the original double-stranded DNA molecule. 
In PCR, a DNA sequence that a researcher wants to amplify, called the "target" sequence, 
undergoes about thirty rounds of replication in a small reaction tube. During each 
replication cycle, the number of molecules of the target sequence doubles, because the 
products and templates of one round of replication all become the templates for the next 
round. After n rounds of replication, 2n copies of the target sequence are theoretically 
produced. After thirty cycles, PCR can produce 230 or more than ten billion copies of a single 
target DNA sequence. This is called a polymerase chain reaction because DNA polymerase 
catalyzes a chain reaction of replication. 
 
Figure 6. PCR is used to enlarge a few pieces of DNA which would create thousands to millions of 
copies of that one sample of DNA. 
2.3. Gel electrophoresis methods 
Gel electrophoresis is a method used in clinical chemistry to separate proteins by charge and 
or size (IEF agarose, essentially size independent) and in biochemistry and molecular biology 
to separate a mixed population of DNA and RNA fragments by length, to estimate the size of 
DNA and RNA fragments or to separate proteins by charge [19]. Nucleic acid molecules are 
separated by applying an electric field [20] to move the negatively charged molecules through 
an agarose matrix. Shorter molecules move faster and migrate farther than longer ones 
because shorter molecules migrate more easily through the pores of the gel. This phenomenon 
is called sieving. Proteins are separated by charge in agarose because the pores of the gel are 
too large to sieve proteins. Gel electrophoresis can also be used for separation of nanoparticles. 
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Gel electrophoresis uses a gel as an anticonvective medium and or sieving medium during 
electrophoresis, the movement of a charged particle in an electrical field. Gels suppress the 
thermal convection caused by application of the electric field, and can also act as a sieving 
medium, retarding the passage of molecules; gels can also simply serve to maintain the 
finished separation, so that a post electrophoresis stain can be applied [21].DNA Gel 
electrophoresis is usually performed for analytical purposes, often after amplification of 
DNA via PCR, but may be used as a preparative technique prior to use of other methods 
such as mass spectrometry (Fig.7), RFLP, PCR, cloning, DNA sequencing, or Southern 
blotting [22] for further characterization. 
 
Figure 7. Mass spectrometry 
2.4. Hybridization methods 
In situ hybridization is a technique used to detect specific DNA and RNA sequences in a 
biological sample. Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are 
macromolecules made up of different sequences of four nucleotide bases (adenine, guanine, 
uracil, cytosine, and thymidine). In situ hybridization takes advantage of the fact that each 
nucleotide base binds with a complementary nucleotide base. For instance, adenine binds 
with thymidine (in DNA) or uracil (in RNA) using hydrogen bonding. Similarly, guanine 
binds with cytosine. 
In a specialized molecular biology laboratory, researchers can make a sequence of 
nucleotide bases that is complementary to a target sequence that occurs naturally in a cell (in 
a gene, for example). When this complementary sequence is exposed to the cell, it will bind 
with that naturally occuring target DNA or RNA in that cell, thus forming what is known as 
a hybrid. The complementary sequence thus can be used as a "probe" for cellular RNA or 
DNA. 
Thus, the term "hybridization" refers to the chemical reaction between the probe and the 
DNA or RNA to be detected. If hybridization is performed on actual tissue sections, cells, or 
isolated chromosomes in order to detect the site where the DNA or RNA is located, it is said 
to be done "in situ." By contrast, "in vitro" hybridization takes place in a test tube or other 
apparatus, and is used to isolate DNA or RNA, or to determine sequence similarity of two 
nucleotide segments. 
Application of the Probe for DNA or RNA to Tissues or Cells: In situ hybridization allows us 
to learn more about the geographical location of, for example, the messenger RNA (mRNA) 
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in a cell or tissue. It can also tell us where a gene is located on a chromosome. Obviously, a 
detection system must be built into the technique to allow the cytochemist to visualize and 
map the geography of these molecules in the cells in question. 
When in situ hybridization was first introduced, it was applied to isolated cell nuclei to 
detect specific DNA sequences. Early users applied the techniques to isolated chromosomal 
preparations in order to map the location of genes in those chromosomes. The technique has 
also been used to detect viral DNA in an infected cell. In situ hybridization of RNA has also 
been used to show that RNA synthesis (transcription) occurs in the nucleus, while protein 
synthesis (translation) occurs in the cytoplasm. 
2.5. Nucleic acid sequencing 
A process by which the sequence of nucleotides along a strand of DNA is determined. 
Originally a difficult process to carry out, DNA sequencing can now be done routinely by 
machines. The completion of the Human Genome Project in 2000 produced the largest DNA 
sequence ever assembled. To carry out the sequencing of the human genome, scientists cut 
the DNA up into short fragments, sequenced these fragments simultaneously, and then 
assembled the entire genome by using sophisticated computer techniques to match the 
fragments to each other.  
2.5.1. DNA microarrays 
Gene expression profiling using DNA microarrays holds great promise for the future of 
molecular diagnostics. This technology allows, in one assay, for simultaneous assessment of 
the expression rate of thousands of genes in a particular sample. The 2 types of DNA 
microarrays that are widely used are cDNA microarrays and oligonucleotide/ DNA chips. 
 
Figure 8. A lung primary tumor, for example, has a different fingerprint than an ovarian or colonic 
primary. This feature can be exploited in the setting of tumors of unknown primary, in which DNA 
microarrays have been shown to predict the correct primary site with an amazing accuracy rate of 99%. 
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In cDNA microarrays, DNA sequences complementary to a library of mRNA from 
thousands of genes are mechanically placed on a single glass slide. The immobilized cDNA 
sequences serve as anchoring probes to which mRNA extracted from the tested sample will 
specifically attach during hybridization. If the tested mRNA is first tagged with a 
fluorescent dye, the intensity of fluorescence at each anchoring probe location will be 
proportional to the amount of mRNA (degree of expression) of the gene at that location. A 
microarray reader displays the intensity of fluorescence at each cDNA location as a colored 
dot per gene location on a grid. 
The applications of these technologies are limitless. By analyzing and comparing hundreds 
of tumor samples, databases of gene expression ‘‘fingerprints’’ are being built and specific 
patterns of expression linked to both prognosis and outcome of therapy.11–16 Patterns of 
gene expression in tumors are also linked to the primary site of origin (Fig.8). 
2.5.2. Proteomics 
The term proteomics indicates a large-scale characterization of the entire protein complement of 
a cell type, tissue, or organism. Two-dimensional gel electrophoresis has been, and remains, a 
widely used technique that offers a high-resolution capacity to separate and characterize 
proteins in complex mixtures. More recently, 2-dimensional electrophoresis (Fig.9) has been 
coupled with mass spectrometry analysis as a means to characterize complex milieus under 
study [23, 24]. Several mass spectrometry platforms are commercially available. We will focus 
our discussion on surface-enhanced laser desorption/ionization technology [25, 26].  
 
Figure 9. Proteomic analysis of nipple aspirate fluids using 2-dimensional gel electrophoresis. Spots in the 
bottom panel (enlarged from the top panel) indicate proteins expressed solely by nipple aspirate fluids 
from breasts containing tumor and not by the contralateral control breast. Copyright 2002 American 
Cancer Society. Reprinted with permission of Wiley-Liss, Inc, a subsidiary of John Wiley & Sons, Inc. [27]. 
These technology uses matrix-assisted lasers desorption and time-of-flight analysis to allow 
fully automated separation of even minute amounts of protein components. The assay 
exploits variations in mass and electric charge of different protein components in a given 
sample (e.g., serum). It is the variation in time of flight—based on the mass/charge ratio of 
each peptide—that allows for separation of the different protein components. With the aid 
of computer analyses, results are displayed as peaks representing the different peptide 
components of a given sample. By characterizing proteomic ‘‘fingerprints’’ associated with a 
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particular type of tumor, it is possible to identify an unknown sample that matches a 
previously defined fingerprint. This can be done on the basis of the ‘‘peaks’’ pattern without 
knowing which protein each peak represents. Appropriate integration of genomic and 
proteomic data is crucial to elucidate protein functions as they relate to pathogenesis. This 
integration will help highlight potential pathogenically important epigenetic deviations at 
the protein level.18 Integration of genomics and proteomics will no doubt facilitate 
discovery of novel drug target proteins and biomarkers of diseases. 
3. Molecular pathological diagnostics  
Molecular diagnostics can be widely defined as the measurement of deoxyribonucleic acid 
(DNA), ribonucleic acid (RNA), proteins, or other metabolites to detect certain genotypes, 
mutations, or biochemical changes that may be associated with certain states of health or 
disease, main applications of molecular genetic testing … [28]. The emergence of molecular 
diagnostics is due to advances in biology that have resulted in an understanding of the 
mechanisms of normal and disease processes at the molecular level. Prior to this 
understanding, many disease states were diagnosed from morphologic observations.  
The first widely used molecular tests were for infectious diseases, such as for hepatitis B and 
C or human papillomavirus (HPV), and this continues to be the largest molecular 
diagnostics market. Certain other fields, such as molecular tests for oncology, inherited 
conditions, cardiovascular disease, neurological disorders, and forensic testing, are rapidly 
growing areas of interest. Additionally, molecular diagnostics can be used to monitor a 
patient’s response to a particular drug treatment. 
Many different biological techniques fall under the “molecular diagnostics” umbrella. One 
of the most common techniques is the polymerase chain reaction (PCR), a method of 
producing large amounts of specifically defined DNA or RNA fragments that can then be 
used for multiple purposes, including pathogen identification and detection of aberrant 
gene expression associated with certain diseases. PCR fragments may also be sequenced to 
detect gene mutations connected to certain disease states, such as the detection of mutations 
in the BRCA1 and BRCA2 genes that are often associated with an increased risk of 
hereditary breast cancer and ovarian cancer. 
3.1. Molecular genetic testing  
Examples of main genetic testing….. [29]. 
 Bone Marrow Transplant Engraftment [Short tandem repeat (STR) polymorphic DNA 
markers used to distinguish patient from donor]. 
3.1.1. Indications for molecular testing 
Allogeneic, HLA-matched hematopoietic stem cell transplantation (BMT) related or non-
related donor. Donor and recipient specific DNA fragment patterns are utilized to 
distinguish the origins of each cell population. 
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3.2. Testing methodology 
Applied Biosystems AmpFLSTR Profiler Plus Kit utilizes short tandem repeat (STR) 
polymorphic DNA markers to distinguish patient and donor cells. Fluorescent multiplex 
polymerase chain reaction (PCR) is used to amplify the markers. 
3.2.1. Interpretation of DNA analysis 
DNA isolated from the WCB’s (lymphoid or myeloid cells) of the patient and donor is 
characterized with 10 polymorphic DNA markers prior to the bone marrow transplantation. 
The patterns are compared and one marker is selected to distinguish donor and patient as 
uniquely different from one another. 
This will be subsequently used to assess the status of donor cell engraftment. In related 
family members one or more of these markers may demonstrate high incidence of non-
identity in the BMT setting. The alleles range in size and heterozygosity. 
In the general population, only identical twins have identical DNA profiles at all of these 
STR loci.When more than one of the ten STR markers has an informative (not identical) 
pattern between patient and donor, the one that demonstrates the most clearly 
distinguished differences in size or mobility is selected to follow engraftment status post-
transplant. Amelogenin distinguishes X and Y chromosomes and may be used when the 
patient and donor are not of the same gender. Enriched subpopulations of hematopoietic 
cells (E.g. T lymphocytes and myeloid cells) may also be assayed 
Specimen Requirements: Peripheral Blood--1 lavender-top (EDTA) tube. Invert several times 
to mix blood. Bone Marrow--Place 1-2 mL of anticoagulated bone marrow in a lavender-top 
(EDTA) tube. Invert several times to mix bone marrow. Do not freeze, forward promptly at 
ambient temperature. Buccal swab, cord blood, blood spots, and frozen tissue. 
 BRCA Ashkenazi Jewish Mutations 
BRCA1 and BRCA2 are human genes that belong to a class of genes known as tumor 
suppressors. Mutation of these genes has been linked to hereditary breast and ovarian cancer.  
A woman's risk of developing breast and/or ovarian cancer is greatly increased if she 
inherits a deleterious (harmful) BRCA1 or BRCA2 mutation. Men with these mutations also 
have an increased risk of breast cancer. Both men and women who have harmful BRCA1 or 
BRCA2 mutations may be at increased risk of other cancers.  
Genetic tests are available to check for BRCA1 and BRCA2 mutations (Fig.10). A blood 
sample is required for these tests, and genetic counseling is recommended before and after 
the tests. If a harmful BRCA1 or BRCA2 mutation is found, several options are available to 
help a person manage their cancer risk. 
Several methods are available to test for BRCA1 and BRCA2 mutations. Most of these 
methods look for changes in BRCA1 and BRCA2 DNA. At least one method looks for 
changes in the proteins [ (PROH-teen) A]  molecule made up of amino acids that are needed 
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for the body to function properly. Proteins are the basis of body structures such as skin and 
hair and of substances such as enzymes, cytokines, and antibodies] produced by these 
genes. Frequently, a combination of methods is used. 
A blood sample is needed for these tests. The blood is drawn in a laboratory, doctor's office, 
hospital, or clinic and then sent to a laboratory that specializes in the tests. It usually takes 
several weeks or longer to get the test results. Individuals who decide to get tested should 
check with their health care provider to find out when their test results might be available. 
 
Figure 10. Genetic tests are to check for BRCA1 and BRCA2 mutations 
 Cystic Fibrosis Mutation Analysis 
Cystic fibrosis (CF) occurs at increased frequency in Caucasians and individuals of 
Ashkenazi Jewish descent, but can occur in any ethnic group (Fig.11). It is a disorder of 
mucus production, primarily affecting the pulmonary, gastrointestinal and reproductive 
systems. Although there is some variability of clinical expression, most individuals with CF 
require lifelong medical care and experience reduced life expectancy. 
Molecular Testing: The preferred sample type is ACD or EDTA anticoagulated blood (pale 
yellow top or lavender top, 3ml), which may be refrigerated up to 48 hours before analysis. 
A mutation panel is tested by PCR followed by oligonucleotide ligation assay using 
commercial analyte specific reagents (ASRs) available through Abbott diagnostics that were 
validated in laboratory. In diagnostic (as opposed to screening) tests, three polymorphisms 
that have the potential to confound mutation analysis are also evaluated along with analysis 
of the intron 8 polypyrimidine tract polymorphism (5T, 7T and 9T). Intron 8 analysis is also 
done as a reflex test when an R117H mutation is detected because 5T in cis with R117H is a 
disease-related allele. Individuals of Ashkenazi Jewish descent are tested for D1152H in 
addition to the routine panel of mutations. Testing for D1152H is performed by the Third 
Wave InPlexTM CF Assay. Results are reported as either consistent with a diagnosis of CF 
(two mutations found); at least carrier status (one mutation identified); or no detectable 
mutation (which reduces the probability of CF or carrier status). We recommend that 
screening (carrier testing) of the partner of a carrier be sent to an outside laboratory where 
more extensive mutation testing is possible. When screening is simultaneously requested on 
both partners, testing is done in-house. 
 
Molecular Histopathology 267 
 DNA Fingerprinting 
The process begins with a sample of an individual's DNA (typically called a "reference 
sample"). The most desirable method of collecting a reference sample is the use of a buccal 
swab, as this reduces the possibility of contamination. When this is not available (e.g. 
because a court order may be needed and not obtainable) other methods may need to be 
used to collect a sample of blood, saliva, semen, or other appropriate fluid or tissue from 
personal items (e.g. toothbrush, razor, etc.) or from stored samples (e.g. banked sperm or 
biopsy tissue). Samples obtained from blood relatives (biological relative) can provide an 
indication of an individual's profile, as could human remains which had been previously 
profiled. 
 
Figure 11. Cystic fibrosis (CF) 
A reference sample is then analyzed to create the individual's DNA profile using one of a 
number of techniques, discussed below. The DNA profile is then compared against another 
sample to determine whether there is a genetic match. 
Another technique, AmpFLP, or amplified fragment length polymorphism was also put into 
practice during the early 1990s. This technique was also faster than RFLP analysis and 
used PCR to amplify DNA samples. It relied on variable number tandem repeat (VNTR) 
polymorphisms to distinguish various alleles, which were separated on a polyacrylamide 
gel using an allelic ladder (as opposed to a molecular weight ladder). Bands could be 
visualized by silver staining the gel. One popular locus for fingerprinting was the D1S80 
locus. As with all PCR based methods, highly degraded DNA or very small amounts of 
DNA may cause allelic dropout (causing a mistake in thinking a heterozygote is a 
homozygote) or other stochastic effects. In addition, because the analysis is done on a gel, 
very high number repeats may bunch together at the top of the gel, making it difficult to 
resolve. AmpFLP analysis can be highly automated, and allows for easy creation of 
phylogenetic trees based on comparing individual samples of DNA. Due to its relatively 
low cost and ease of set-up and operation, AmpFLP remains popular in lower income 
countries. 
 Factor V Mutation Analysis 
Factor V Leiden (F5) point mutation G1691A (Formerly FVL) (Fig.12). 
 Histopathology – Reviews and Recent Advances 268 
Indications for Molecular Testing. Family history of venous thrombosis- Unprovoked 
thrombotic event at <45 years of age- Women with multiple stillbirths or spontaneous 
abortions - Confirmation of diagnosis of F5 by non-molecular means  
Testing Methodology. Screening utilizes polymerase chain reaction (PCR) and restriction 
fragment length polymorphism (RFLP) techniques to detect the Factor V Leiden point 
mutation (G1691A). The base pair change results in the loss of a recognition site for the 
restriction enzyme MnlI. (PCR is utilized pursuant to a license agreement with Roche 
Molecular Systems, Inc.) 
Interpretation of DNA analysis. Factor V Leiden, a point mutation (G1691A) in the gene 
coding for coagulation Factor V, has been associated with an increased risk of venous 
thrombosis due to increased resistance to degradation of factor V by activated Protein C. For 
individuals presenting with venous thrombosis, FVL occurs in 11 – 20% of those in all age 
groups and 50% of individuals under 50 years of age. Heterozygosity for this mutation 
produces a 7 – fold increase relative risk of venous thrombosis. Approximately 5% of 
Caucasians are heterozygous for this mutation. The homozygous occurrence of this 
mutation has been associated with an 80 – fold      increased risk for venous thrombosis. 
Specimen Requirements [Peripheral blood--1 lavender-top (EDTA) tube. Invert several times 
to   mix blood].     
 
Figure 12. Factor V Leiden (F5) point mutation G1691A (Formerly FVL) 
 Familial Mediterranean Fever Mutation 
The MEFV gene (Fig.13) provides instructions for making a protein called pyrin (also known 
as marenostrin). Although pyrin's function is not fully understood, it likely assists in 
keeping the inflammation process under control. Inflammation occurs when the immune 
system sends signaling molecules and white blood cells to a site of injury or disease to fight 
microbial invaders and facilitate tissue repair. When this has been accomplished, the body 
stops the inflammatory response to prevent damage to its own cells and tissues. 
Pyrin is produced in certain white blood cells (neutrophils, eosinophils, and monocytes) that 
play a role in inflammation and in fighting infection. Pyrin may direct the migration of 
white blood cells to sites of inflammation and stop or slow the inflammatory response when 
it is no longer needed. Pyrin also interacts with other molecules involved in fighting 
infection and in the inflammatory response. Research indicates that pyrin helps regulate 
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inflammation by interacting with the cytoskeleton, the structural framework that helps to 
define the shape, size, and movement of a cell. 
 
Figure 13. Familial Mediterranean Fever Mutation & Fig.14: Fragile X syndrome (FXS), Martin–Bell 
syndrome. 
 Fragile X Mutation Analysis 
Fragile X syndrome (FXS), Martin–Bell syndrome, or Escalante's syndrome (more commonly 
used in South American countries,Fig.14), is a genetic syndrome that is the most common 
known single-gene cause of autism and the most common inherited cause of mental 
retardation among boys. It results in a spectrum of intellectual disability ranging from mild 
to severe as well as physical characteristics such as an elongated face, large or protruding 
ears, and larger testes (macroorchidism), behavioral characteristics such as stereotypical 
movements (e.g. hand-flapping), and social anxiety. 
Fragile X syndrome is associated with the expansion of the CGG trinucleotide repeat affecting 
the Fragile X mental retardation 1 (FMR1) gene on the X chromosome, resulting in a failure to 
express the fragile X mental retardation protein (FMRP), which is required for normal neural 
development. Depending on the length of the CGG repeat, an allele may be classified as 
normal (unaffected by the syndrome), a premutation (at risk of fragile X associated disorders), 
or full mutation (usually affected by the syndrome). A definitive diagnosis of fragile X 
syndrome is made through genetic testing to determine the number of CGG repeats. Testing 
for premutation carriers can also be carried out to allow for genetic counseling. 
This molecular test detects the DNA expansion observed in approximately 99% of Fragile X 
Syndrome carriers or affected individuals. Normal individuals have between about 6 and 50 
FMR1 CGG repeats. The FMR1 CGG repeats tend to undergo expansion when repeat 
numbers exceed about 50. Premutation carrier females and normal transmitting males have 
between about 50 and 200 repeats. Affected males typically have many more than 200 
repeats. Females with an X chromosome having greater than 200 FMR1 CGG repeats may or 
may not be affected depending on X chromosome inactivation patterns. FMR1 CGG repeats 
of about 50 to 200 show a dynamic instability directly related to their length, to the sex of the 
transmitting individual, and to subtle DNA sequence variation within the repeat itself. 
Premutation alleles tend to be unstable when transmitted by females and stable when 
transmitted by males (stability in males may be a consequence of selection against expanded 
FMR1 CGG alleles during spermatogenesis). Repeats greater than about 90-100 repeats have 
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nearly a 100% risk of expansion into the affected range when transmitted by a female. The 
FMR1 CGG repeat demonstrates significant somatic instability when repeat sizes enter the 
premutation range. Premutation and larger sized CGG repeats determined from peripheral 
blood DNA may not reflect FMR1 CGG repeat sizes in other tissues. 
 Friedreich's Ataxia Mutation Analysis 
Friedreich's ataxia is an inherited disease that causes progressive damage to the nervous 
system, resulting in symptoms ranging from gait disturbance to speech problems; it can also 
lead to heart disease and diabetes (Fig.15). 
 
Figure 14. (A) The lower cervical cord (C6) is atrophic, and the myelin of the posterior column shows 
marked pallor (Klüver-Barrera stains originally×6.0). (B) Numerous axonal spheroids immunostained 
by antineurofilament antibody, SMI-31 (brown, arrow head) and corpora amylacea by antibiquitin 
antibody (purple, arrow) in the posterior column nucleus (originally×514). (C) The gracile fasciculi of 
the upper cervical cord (C3, left) and lower lumbar cord (L2, right) (toluidine blue stain×514), show 
decreased axon density and thin myelin. These changes are more marked in C3 than those in L2. (D) 
Lower medulla (Holzer stain originally×4.4). Marked gliosis is present in the gracile and cuneate nuclei. 
(E) The dorsal root ganglion of right C7 (periodic acid-Shiff originally×210). Ganglion cells are well 
preserved and Nageotte's nodules are very rare. (F) Cerebellar hemisphere (haematoxylin and eosin 
originally×64). There is focal loss of Purkinje cells. Purkinje cells have almost disappeared in the upper 
folium, but are relatively preserved in the lower folium (arrow). (G) Retina (haematoxylin and eosin 
originally×257). The outer segment layer of photoreceptor cells has disappeared (asterisk) and the outer 
nuclear layer is not obvious. The inner layers of the retina are thin and atrophic (arrow). Journal of 
Neurology, Neurosurgery & Psychiatryjnnp.bmj.com- J Neurol Neurosurg Psychiatry 2000;68:521-525 
doi:10.1136/jnnp.68.4.521. Analysis of the GAA trinucleotide repeats expansion in the FXN gene of individuals 
with Friedreich ataxia. (A) The length of the GAA repeat region in each allele of the FXN gene was determined by 
long-range PCR and agarose gel electrophoresis. Patient 1, 770 and 870 repeats; Patient 2, 760 and 1170 repeats; 
Patient 3, 790 and 940 repeats; Patient 4, 650 and 1140 repeats; L: DNA size ladder. (B) PCR products following 
digestion with MboII. Complete digestion of pure GAA repeat sequences leaves flanking regions of 157 bp and 125 
bp. The occurrence of an additional band of ~680 bp in lane P4 indicates the presence of non-GAA sequence within 
the GAA trinucleotide repeat expansion region [31].  
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The ataxia of Friedreich's ataxia results from the degeneration of nerve tissue in the spinal 
cord, in particular sensory neurons essential (through connections with the cerebellum) for 
directing muscle movement of the arms and legs. The spinal cord becomes thinner and 
nerve cells lose some of their myelin sheath (the insulating covering on some nerve cells that 
helps conduct nerve impulses). 
The condition is named after the German physician Nikolaus Friedreich, who first described 
it in the 1860s [30]. 
 Hereditary Hemochromatosis 
Hemochromatosis gene (HFE) testing is a blood test used to check for hereditary 
hemochromatosis, an inherited disorder that causes the body to absorb too much iron. The 
iron then builds up in the blood, liver, heart, pancreas, joints, skin, and other organs (Fig.16). 
In its early stages, hemochromatosis can cause joint and belly pain, weakness, lack of 
energy, and weight loss. It can also cause scarring of the liver (cirrhosis), darkening of the 
skin, diabetes, infertility, heart failure, irregular heartbeats (arrhythmia), and arthritis. But 
many people do not have symptoms in the early stages.  
 
Figure 15. Perls’ Prussian blue staining of liver sections from HFE+/+ and HFE−/− mice fed control diet 
(A–D) or control diet supplemented with 2% (wt/wt) carbonyl iron (E–H). Shown are low-power views 
(A, C, E, and G) and high-power views (B, D, F, and H) of sections. A and B show the absence of 
stainable iron in the +/− mouse liver fed the control diet. C and D show prominent stainable iron in 
hepatocytes with periportal predominance in liver from HFE−/− mice fed the control diet. E and F show 
iron accumulation in HFE+/+ mouse liver in response to iron loading. G and H show the stainable iron in 
the HFE−/− mice after 2 weeks of feeding with the iron-supplemented diet. The arrows indicate the 
location of branches of the portal vein. (Bars: A, C, E, and G = 50 μm in the low-power views; B, D, F, 
and H = 20 μm in the high-power views.) 
In men, hereditary hemochromatosis is usually found between the ages of 40 and 60. In 
women, it is not usually found until after menopause because, until that time, women 
regularly lose blood and iron during their monthly periods. Genetic testing for 
hemochromatosis involves a simple blood test. DNA from the blood is extracted and the 
HFE gene is tested for two specific mutations in the gene known to cause the disease in most 
people. There are two laboratory techniques typically used to detect the two mutations: 
allele-specific oligonucleotide hybridization (ASO) and restriction fragment length 
polymorphism (RFLP) analyses. Both of these tests are designed to detect whether a specific 
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mutation is present or absent in a DNA sample. These tests will also determine if an 
individual is a carrier of either mutation. The two mutations typically tested for are most 
commonly called C282Y and H63D. The mutations are named based on their location within 
the HFE gene and the change that they cause in the gene's instructions. The two mutations 
differ in how frequently they are found in the population, and in how severe your 
hemochromatosis is if you have them. There are other rare mutations that may predispose 
individuals towards abnormal iron storage. However they are not yet part of most 
laboratories testing panels for hemochromatosis. 
 Huntington Disease 
Huntington's disease (HD) is a neurodegenerative genetic disorder that affects muscle 
coordination and leads to cognitive decline and psychiatric problems (Fig.17). It typically 
becomes noticeable in mid-adult life. HD is the most common genetic cause of abnormal 
involuntary writhing movements called chorea, and indeed the disease used to be called 
Huntington's chorea. 
Because HD follows an autosomal dominant pattern of inheritance, there is a strong 
motivation for individuals who are at risk of inheriting it to seek a diagnosis. The genetic 
test for HD consists of a blood test which counts the numbers of CAG repeats in each of the 
HTT alleles [32]. A positive result is not considered a diagnosis, since it may be obtained 
decades before the symptoms begin. However, a negative test means that the individual 
does not carry the expanded copy of the gene and will not develop HD [33]. 
 
Figure 16. Huntington's disease (HD) is a neurodegenerative genetic disorder that affects muscle 
coordination and leads to cognitive decline and psychiatric problems. Neuron with inclusion (stained 
orange) caused by HD, image width 250 μm. 
A pre-symptomatic test is a life-changing event and a very personal decision [33]. The main 
reason given for choosing testing for HD is to aid in career and family decisions [33]. Over 
95% of individuals at risk of inheriting HD do not proceed with testing, mostly because 
there is no treatment.[ 38] A key issue is the anxiety an individual experiences about not 
knowing whether they will eventually develop HD, compared to the impact of a positive 
result [33] . Irrespective of the result, stress levels have been found to be lower two years 
after being tested, but the risk of suicide is increased after a positive test result [33] . 
Individuals found to have not inherited the disorder may experience survivor guilt with 
regard to family members who are affected [12]. Other factors taken into account when 
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considering testing include the possibility of discrimination and the implications of a 
positive result, which usually means a parent has an affected gene and that the individual's 
siblings will be at risk of inheriting it. Genetic counseling in HD can provide information, 
advice and support for initial decision-making, and then, if chosen, throughout all stages of 
the testing process.[39] Counseling and guidelines on the use of genetic testing for HD have 
become models for other genetic disorders, such as autosomal dominant cerebellar ataxias 
[38]. Presymptomatic testing for HD has also influenced testing for other illnesses with 
genetic variants such as polycystic kidney disease, familial Alzheimer's disease and breast 
cancer [34].  
4. Molecular oncology testing  
 B-Cell Gene Rearrangement  
The B- and T-cell rearrangement test [35] can detect a monoclonal population of B- and T-
cells, strongly indicative of neoplasia. This is accomplished through the use of DNA probes. 
The presence of a unique band on the Southern blot (Fig.18) signifies a monoclonal gene 
rearrangement, which can make or confirm a diagnosis of a lymphoproliferative disorder 
and classify the lineage as B- or T-cell. T-cell neoplasms generally behave more aggressively 
than B-cell neoplasms, which can have important implications for prognosis and therapy. 
The unique gene rearrangement "signature" can be followed during and after therapy to 
document remission or recurrence. The most commonly examined samples are from the 
blood, bone marrow, and lymph nodes, but any tissue or fluid suspected of harboring a 
lymphoid neoplasm can be examined. 
 
Figure 17. B-Lymphocyte Immunoglobulin; Heavy Chain Gene Rearrangement. Detection of 
monoclonal B-cell populations in B-lymph proliferative disorders. 
This test is indicated for the accurate differentiation of malignant vs. benign 
lymphoproliferative disorders and for establishing T tumor cell lineage. Clonal 
proliferations of T lymphocytes can be detected by the identification of specific DNA 
rearrangements in the T-cell gamma chain antigen receptor gene. The majority of 
lymphocytic leukemias and non-Hodgkin's lymphomas arise from a clonal proliferation of a 
single lymphoid cell that has become aberrant. T cells normally differentiate from stem 
 Histopathology – Reviews and Recent Advances 274 
(precursor) cells in a highly specific and sequential manner. The malignant transformation 
may take place at any stage in the maturation process and when it occurs, the resulting 
malignant clone bears the characteristics of the originally transformed cell and is called 
monoclonal. Some of the early events in the maturation process of lymphoid cells involve 
specific nucleic acid rearrangements within the gamma chain antigen receptor gene in T-cells. 
 
Figure 18. In this image, hundredfold magnification of a single sperm precursor cell shows the 
chromosomes – in green – and the places where these chromosomes are most likely to break apart and 
re-form, called genetic recombination hotspots – in red. Genetic rearrangements at these hotspots have 
the potential to shuffle maternal and paternal chromosomes, the end results of which ensure that the 
genetic information in every sperm cell is unique. Source: Fatima Smagulova, Ph.D., USU, and Kevin 
Brick, Ph.D., NIDDK, NIH. 
This test is indicated for the accurate differentiation of malignant vs. benign 
lymphoproliferative disorders and for establishing B tumor cell lineage. Clonal 
proliferations of B-lymphocytes can be detected by the identification of specific DNA 
rearrangements in the immunoglobulin gene. The majority of lymphocytic leukemias and 
non-Hodgkin's lymphomas arise from a clonal proliferation of a single lymphoid cell that 
has become aberrant. B cells normally differentiate from stem (precursor) cells in a highly 
specific and sequential manner. The malignant transformation may take place at any stage 
in the maturation process and when it occurs the resulting malignant clone bears the 
characteristics of the originally transformed cell and is called monoclonal. Some of the early 
events in the maturation process of lymphoid cells involve specific nucleic acid 
rearrangements within the immunoglobulin genes in B cells. To detect B cell gene 
rearrangements using PCR, primers are constructed to amplify the DNA between the 
conserved framework (FR) and joining (J) regions. These conserved regions lie on either side 
of an area within the V-J region where programmed genetic rearrangements occur during 
maturation. In the germline configuration found in somatic cells, these areas are widely 
separated (by more than 70KB) making PCR amplification across the area impossible. The 
sequence alteration brought about by gene rearrangement brings these regions into close 
proximity, making the area of amplifiable length. Each B cell has a single productive V-J 
rearrangement that is unique in both length and sequence. The template-free incorporation 
of nucleotides (N-regions) between the spliced V, D, and J gene segments also adds 
uniqueness to the PCR product. Therefore, when this region is amplified using DNA 
 
Molecular Histopathology 275 
primers that flank this region, a clonal population of cells yields one or two prominent 
amplified products (amplicons) within the expected size ranges. Two products are produced 
in cases when the initial rearrangement was non-productive and was followed by 
rearrangement of the other homologous chromosome. In contrast, DNA from a normal or 
polyclonal population produces a bell-shaped curve (or Gaussian distribution) of amplicon 
products that reflects the heterogeneous population of V-J region rearrangements. Specimen: 
Whole blood, bone marrow or tissue(10 mL blood; 4 mL bone marrow; 0.2 g or more of tissue) 
 BCL-2 Gene Rearrangement 
Gene Rearrangement bcl-2; Major Breakpoint Region (MBR); minor cluster region (mcr); 
t(14:18) Translocation. Applies to Follicular B-Cell Lymphomas. A translocation between 
immunoglobulin genes (heavy chain or light chain genes) and bcl-2 results in the over 
expression of bcl-2 protein and thus the expansion of B cells due to inhibition of cell death. 
This type of translocation is found in 100% at small cleaved type, 76% to 85% at mixed cell 
and 59% to 75% at large cell types of Bcell lymphoma. It is found in some cases of chronic 
lymphocytic leukemia, acute lymphoblastic leukemia, and small noncleaved cell lymphoma 
as well as some cases of Hodgkin's lymphoma and myeloid neoplasms. The t(14;18) is rarely 
detected in monocytoid B-cell lymphoma and MALT lymphomas. bcl-2 rearrangement is not 
pathognomonic for lymphomas. It is found in 10% of reactive lymph nodes, and in some 
normal cells (eg, lymphoid and myeloid precursors, medullary thymocytes, T cells, 
nongerminal center B cells, and plasma cells). It is not expressed in centers. 
 BCR-ABL Gene Rearrangement 
Translocation bcr/abl; Gene Rearrangement bcr; Philadelphia Chromosome; t (9:22) Applies 
to Acute Myelogenous Leukemia (ALL); Chronic Myelogenous Leukemia (CML) 
 BRAF Gene Mutation Detection 
BRAF is downstream of KRAS in a signaling pathway involved in cell cycling. Both KRAS 
and BRAF are prone to mutations in sporadic colorectal carcinomas (CRC). 
This assay is capable of detecting the V600E mutation in exon 15 of BRAF. The much rarer 
V600A or V600G mutations would also be detectable. Detection includes PCR amplification 
and a single-base extension reaction that generates allele-specific fluorescently labeled 
probes, detectable by capillary electrophoresis. 
Several studies have demonstrated that mutations in KRAS lead to constitutive activation of 
this pathway, which may lead to cancer progression, and this activation results in a failure 
to respond to anti-EGFR therapy. Recent published results indicate that mutations in the 
KRAS gene are present in approximately 40% of patients with metastatic colorectal 
adenocarcinoma, and the presence of a K-ras mutation isassociated with resistance to 
cetuximab and panitumumab. BRAF mutations are responsible for an additional 12-15% of 
patients who fail to respond to anti-EGFR treatment. This finding suggests that testing for 
the BRAF V600E mutation can compliment KRAS mutation analysis and may be as 
important as KRAS testing for treatment decisions. 
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 c-kit Mutation Detection for Systemic Mastocytosis 
Nucleotide substitutions at and adjacent to codon 816 in the catalytic domain of c-kit are 
common in SM. Detection of a codon 816 c-kit mutation is included as a minor diagnostic 
criterion in the WHO’s diagnostic criteria for SM. Determining mutational status of the c-kit 
gene also has pharmacogenetic implications in patients considered for investigational mast 
cell cytoreductive therapies and targeted small-molecule tyrosine kinase inhibitors 
Sequencing analysis. Polymerase Chain Reaction (PCR) is performed for DNA amplification. 
Primers are designed specifically for exon 17 of the c-kit gene. PCR products are sequenced 
and analyzed on the ABI 3130xl Genetic Analyzer. 
 JAK2 Mutation Analysis  
The JAK2 V617F substitution, located in the pseudokinase domain of JAK2, relieves the 
autoinhibition of its kinase activity; the resulting constitutively active kinase augments 
downstream JAK2-STAT signaling pathways. Other JAK2 mutations in humans include 
translocations, point mutations, deletions, and insertions [36, 37]. However, the most 
frequent mutations are those seen in patients with JAK2 V617F-negative polycythemia vera 
or idiopathic erythrocytosis (Fig.20 and 21), the exon 12 mutations. Documented high-
frequency JAK2 exon 12 mutations include in-frame deletions, missense, and tandem point 
mutations such as del/F537-K539ins/L, del/N542-E543, K539L, and H538QK539L [38]. 
Whereas JAK2 V617F mutations are typically homozygous (by mitotic recombination), exon 
12 mutations are often heterozygous in patients with polycythemia vera. In addition, exon 
12 mutations can induce cytokine-independent hypersensitive proliferation in 
erythropoietin-expressing cell lines and are sufficient for the development of a polycythemia 
vera-like phenotype in a murine model.  
 
Figure 19. Structural analysis of JAK2V617F kinase domain mutations. (a) Cartoon and transparent 
surface representation of ruxolitinib-docked JAK2 kinase domain (a, b) (left) and JAK2 with location of 
point mutations that lead to drug resistance (right). N-terminal lobe (salmon), C-terminal lobe (gray), 
glycine loop (purple), activation loop (blue) and hinge region (red) form the boundaries for the binding 
site of ruxolitinib (stick representation in yellow (carbon) and blue (nitrogen)). The I960V side chain 
(purple) is buried within the protein interior. (b) Enlarged ruxolitinib-binding pocket with secondary 
structure elements (cartoon) and the interactions of the side chains (labeled sticks) with the inhibitor. 
Hydrogen bonds between the inhibitor and the protein are indicated as dotted yellow lines (one 
hydrogen bond between backbone of Y931 and L932; and two hydrogen bonds with R980 and N981 and 
pyrrolopyrimidine ring of the inhibitor; additional hydrogen bonds are with water molecules (cyan 
spheres) . Mutated amino acids are labeled red (right panels). (c) Surface electrostatic potential 
representation of the native (left) and G935R (right) containing JAK2 JH1 domain with ruxolitinib. 
Charged surfaces are displayed in shades of blue (positive), red (negative) and white (non-polar) [39]. 
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Figure 20. Bone marrow morphology demonstrating both dysplastic and proliferative features in a JAK 
V617F negative patient (n. 511; A-D) and a patient with the mutation (n. 510; E-I). Ringed sideroblastosis 
(A,E) associated with immaturity, megaloblastoid changes and abnormal nuclear budding (arrows) and 
binuclearity (asterix) of erythroblasts (B,C,F,G). Dysgranulopoiesis with numerous hypogranular 
(arrowheads) myeloid cells (B,F,G; Pappenheim’s stain). Evidence of both small megakaryocytes with 
round nuclei and mature cytoplasm (C,H) and large multinucleated forms (D, I). A, E, Perls’ stain; B-D, 
F-I, Pappenheim’s stain; × 1000.  
 KRAS Gene Mutation Detection 
Mutations in the KRAS oncogene are highly prevalent in human tumors, and they most 
commonly occur in codons 12, 13, and 61. K-ras mutations have been detected in pancreatic, 
colorectal, lung, endometrial, gallbladder, and thyroid cancer at variable frequency. 
Accumulating evidence indicates that these mutations may play a role in prognosis and 
drug response. Specifically, recent published results indicate that mutations in the KRAS 
gene are present in approximately 40% of patients with metastatic colorectal 
adenocarcinoma, and the presence of a K-ras mutation is associated with resistance to 
cetuximab and panitumumab. 
The ViennaLab K-ras StripAssay kit will detect 10 KRAS gene mutations in codons 12 and 
13: G12V, G12D, G12L, G12S, G12A, G12I, G12C, G12R, G13C and G13D. 
Specimen Formalin-fixed paraffin-embedded (FFPE) tissue, 10 precut, unstained slides from 
paraffin block in 10 μm (10-micron) sections or formalin-fixed paraffin-embedded tissue 
block containing ≥50% tumor. Either option needs to be accompanied by an H&E reference 
slide. Detection includes PCR amplification using biotinylated primers, reverse 
hybridization of PCR products to test strips containing specific mutant oligonucleotide 
probes, and visualization of bound products with streptavidin-alkaline phosphatase and 
color substrates. 
 Microsatellite Instability 
Microsatellites, also known as Simple Sequence Repeats (SSRs) or short tandem repeats 
(STRs), are repeating sequences of 2-6 base pairs of DNA.  
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Microsatellites are typically co-dominant. They are used as molecular markers in genetics, 
for kinship, population and other studies. They can also be used to study gene duplication 
or deletion. Microsatellites are also known to be causative agents in human disease, 
especially neurodegenerative disorders and cancer. 
In cells with mutations in DNA repair genes, however, some of these sequences accumulate 
errors and become longer or shorter. The appearance of abnormally long or short 
microsatellites in an individual's DNA is referred to as microsatellite instability. 
Microsatellite instability (MSI) is a condition manifested by damaged DNA due to defects 
in the normal DNA repair process. Sections of DNA called microsatellites, which consist of a 
sequence of repeating units of 1-6 base pairs in length, become unstable and can shorten or 
lengthen. Microsatellites are also known as simple sequence repeats (SSRs). Specimen,1 
normal tissue and 1 tumor tissue. Normal tissue may be substituted by a sample  blood Each 
tissue sample must be ≥25 mg.. Amplification by Polymerase Chain Reaction (PCR) of 5 
microsatellite short tandem repeats and detection of these alleles by electrophoresis and 
sizing on an automated fluorescence detector. 
Muir Torre syndrome [MTS] is a rare autosomal dominant inherited genodermatosis with 
malignant potential. It consists of at least one sebaceous gland tumor such as sebaceous 
adenoma, epithelioma, or carcinoma, with at least one visceral malignancy [40]. 
 
Figure 21. Components of Muir-Torre Syndrome. a). Sebaceous adenoma (100X) b). Colonic mucinous 
adenocarcinoma (100X). 
Genetic mutations have been identified as the cause of inherited cancer risk in some colon 
cancer-prone families. The most common clinical syndromes associated with these 
mutations include familial adenomatous polyposis (FAP) and hereditary non-polyposis 
colorectal cancer (HNPCC). The former is associated with mutations of the APC gene, and 
the latter with mutations of MLH1, MSH2, MSH6, and PMS2 genes [41]. These inherited 
syndromes are estimated to account for only 2% to 6% of colorectal cancer cases overall. 
Turcot syndrome is a clinically defined, inherited syndrome associated with both colorectal 
cancer and a primary brain tumor.  
 PMLRAR Alpha t(15;17) Translocation  
AMLs (Acute Myeloid Leukemias, Fig.23) [42] are characterized with chromosomal 
translocations resulting in the formation of fusion proteins. Understanding PML (Acute 
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Promyelocytic Leukemia Inducer) function has become an area of intense research because 
of its involvement in the pathogenesis of APL (Acute Promyelocytic Leukemia), a distinct 
subtype of Myeloid Leukemia. In the vast majority of APL case studies, the PML gene (on 
Chromosome-15) fuses to the RAR-Alpha gene (Retinoic Acid Receptor-Alpha) (on 
Chromosome-17) as a consequence of reciprocal and balanced chromosomal translocations. 
In the t(15;17) chromosomal translocation, which is specific for APL, PML is found in a 
reciprocal translocation with the RAR-Alpha resulting in the formation of PML-RAR-Alpha 
and RAR-Alpha-PML fusion proteins . In a normal cell Vitamin-A (all-trans-Retinol) from 
dietary sources is converted to all-trans-Retinoic Acid in the liver through Retinol 
Metabolism and all-trans-Retinoic Acid is translocated to tissues by CRABP (Cellular 
Retinoic Acid Binding Protein) where it regulates target genes by binding with RARs 
(Retinoic Acid Receptors). Retinoic Acid is the only metabolite of Vitamin-A which regulates 
gene expression and all-trans-Retinoic Acid, the Carboxylic Acid form of Vitamin-A is of 
biological significance since it has high circulating levels than other isomers of Retinoic 
Acid. Biologically active ligands for the RARs include all-trans-Retinoic Acid, 9-cis-Retinoic 
Acid among others. 13-cis-Retinoic Acid is not a ligand for the RARs, but, it is readily 
converted into a RAR ligand by intracellular reciprocal isomerization. Less is understood 
about the fate of intracellular all-trans-Retinoic Acid is its isomerization to 9-cis-Retinoic 
Acid and 13-cis-Retinoic Acid. The RARs have a conserved modular structure consisting of 
six regions from A-F, viz., AF-1 or A/B (Amino-Terminal Activating Factor-1 Transcriptional 
Activation) Domain; a zinc-finger DBD or C (DNA-Binding Domain); a CoR or D 
(Hinge/Corepressor Binding) Domain; a LBD or AF-2 or E (Ligand-Binding/Transcriptional 
Activation) Domain; and a variable F (Carboxyl-Terminal) Domain. In RAR the DBD binds 
to the RARE (Retinoic Acid Response Element) region in the DNA. The RAREs consists of 
DRs (Direct Repeats) of AGG/TTCA motif with a spacer region of (n)25. Upon Retinoic Acid 
binding, RAR-Alpha regulates Retinoic Acid mediated gene expression and transactivates 
PML target genes critical for the induction of Myeloid Hemopoietic Cells’ terminal 
differentiation. 
In this assay, extracted RNA is subjected to 2 separate quantitative real-time reverse 
transcription-polymerase chain reaction (RT-PCR) procedures to detect the 2 types of 
PML/RARA fusion transcripts (long and short isoforms). An additional amplification for the 
abl gene is performed as a control for sample RNA quality and as a reference for relative 
quantification. The results are reported as positive or negative; the ratio of target 
(PML/RARA) to control (ABL) mRNA is reported for positive specimens. The isoform (short 
or long) is also reported. If available, a previously stored sample will be tested alongside the 
current specimen to assess quantitative changes with time (trend). The analytical sensitivity 
of this test is 1 tumor cell in 100,000 normal cells. 
In APL cells due to t(15;17) chromosomal translocation the fusion protein PML-RAR-Alpha 
retains both DBD and LBD of RAR-Alpha, compete with normal RAR-Alpha for ligand 
binding and inhibits its transcriptional function through aberrant recruitment of HDACs 
(Histone Deacetylases). Recruitment of HDACs to PML also leads to inhibition of p53 
activity and Sumolation. HDACs therefore, represent an ideal candidate for blocking the 
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action of the fusion proteins. PML-RAR-Alpha and RAR-Alpha-PML fusion protein 
expression disrupts formation of NBs and paralyzes Tumor Suppression, Cellular 
Senescence, Mature PML degradation and normal Cell Growth and Survival. Co-expression 
of RAR-Alpha-PML with PML-RAR-Alpha thus results in an increase of Leukemia 
incidence and makes a cell more prone to pathogen invasions. All-trans-Retinoic Acid is a 
standard therapy for the management of APL. However, 13-cis-Retinoic Acid and 9-cis-
Retinoic Acid implication reduce the incidence of secondary head and neck tumors and 
APL, respectively. It is apparent that PML is essential for critical tumor suppressive 
pathways that are deregulated in APL and therapies such as induction of Retinoic Acid and 
As2O3 can be helpful in restoring normal PML function in APL cells that can cause the 
reappearance of NBs, and the reversal of T-Cell Gene Rearrangement. 
 
Figure 22. Under normal conditions PML is a potential Tumor Suppressor and is involved in Cellular 
Senescence, a process that controls Oncogenic Signaling leading to normal Cell Growth and Survival. 
PML is the organizer of nuclear matrix domains, NBs (Nuclear Bodies), with a proposed role in 
Apoptosis control. PML being a member of the RBCC (RING-B-Box-Coiled-Coil) Protein Family, 
contains three Zinc Finger-Like domains (a RING Finger and two B-Boxes) and a Coiled-Coil 
Dimerization domain. PML organizes NBs by targeting proteins such as Sp100 (Nuclear Antigen-
Sp100), p53, Rb (Retinoblastoma) or Daxx onto these domains. These domains are also known as PODs 
(PML Oncogenic Domain/Promyelocytic Oncogenic Domains). PML levels increase during both Ras-
induced Senescence, leading to a dramatic increase in the size and number of PODs. Survival 
factors/Ras signaling induce Cellular Senescence by up-regulating PML gene expression though MAPK 
(Mitogen-Activated Protein Kinase) activation. PML is covalently modified and conjugated to SUMO1 
(Small Ubiquitin Related Modifier-1). This enables PML to form NBs and enhances their interaction 
with other proteins. A specific dephosphorylation event triggered by As2O3 (Arsenic Trioxide) targets 
PML to the nuclear matrix to form Primary PML bodies. Sumolation then induces the maturation to 
Secondary PML bodies. In mature PML-NBs (or Secondary PML bodies), PML forms the outer shell and 
many proteins (Sp100, Rb, p53, Daxx, etc) are found within its electron clear core. DNA damage 
induced activation of p53-dependent Apoptosis requires PML. PML acts as a coactivator for p53 and 
increases acetylation of p53 by the transcriptional coactivator CBP (CREB-Binding Protein). This 
acetylation of p53 is reversed by Sirt (Sirtuin (Silent Mating Type Information Regulation-2 Homolog)) 
releasing p53 into p53 Pathway. PML associates with Daxx-mediated Apoptosis induced by Fas/FasL 
(Fas Ligand) and TNF (Tumor Necrosis Factor)/TNFR (Tumor Necrosis Factor Receptor) and regulates 
the transcriptional repressor activity of Daxx. PML acts with Rb and p53 to promote Ras-induced 
Senescence. PML-Sp100 NBs act against viral invasions. Mature PML-NBs are finally degraded by the 
11S Proteasome Complex. 
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 Immunohistochemistry Stains 
Immunohistochemistry is not considered a molecular technique but it is based on the 
antigen-antibody affinity, it has emerged as a powerful investigative tool that can provide 
supplemental information to the routine morphological assessment of tissues. The use of 
immunohistochemistry to study cellular markers that define specific phenotypes has 
provided important diagnostic, prognostic, and predictive information relative to disease 
status and biology. The application of antibodies to the molecular study of tissue pathology 
(Fig.24) has required adaptation and refinement of immunohistochemical techniques, 
particularly for use in fixed tissues. In contrast to solution-based immunoassays that detect 
relatively abundant native proteins, in fixed tissues the preservation of antigen is variable 
and unpredictable. Thus, the history of immunohistochemistry has been a constant effort to 
improve sensitivity for detection of rare surviving antigenic targets with the ultimate goal of 
integrating tissue-based analysis with proteomic information. 
 
Figure 23. Immunohistochemistry Staining Stages. 
 Nanotechnology in clinical laboratory diagnostics  
Nanotechnologies enable diagnosis at the single-cell and molecule levels, and some can be 
incorporated in current molecular diagnostic methods, such as biochips. Nanoparticles, such 
as gold nanoparticles and quantum dots, are the most widely used, but various other 
nanotechnological devices for manipulation at the nanoscale as well as nanobiosensors are 
also promising for potential clinical applications, main applications of nanotechnology [43] . 
Nanotechnologies will extend the limits of current molecular diagnostics and enable point-of-
care diagnostics, integration of diagnostics with therapeutics, and development of personalized 
medicine. Although the potential diagnostic applications are unlimited, the most important 
current applications are foreseen in the areas of biomarker discovery, cancer diagnosis, and 
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detection of infectious microorganisms. Safety studies are needed for in vivo use. Because of its 
close interrelationships with other technologies, nanobiotechnology in clinical diagnosis will 
play an important role in the development of nanomedicine in the future. 
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